Stocks Forest Laboratories Inc

  • Following are the day’s biggest winners and losers. Find out why shares of Smithfield Foods and Compuware popped while Manitowoc and Las Vegas Sands dropped.

  • Forest Laboratories on Tuesday posted a better-than-expected profit, but shares fell 7.5 percent as the mid-sized drugmaker projected only slightly higher full-year earnings due to expenses to improve its product line.

  • picks_pans_badge.jpg

    The recent gyrations in the markets may have scared some investors away, but two leading  portfolio managers say there are still plenty of value stocks to be snapped up.

  • Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • picks_pans_badge.jpg

    Scott Richter has a set of directions for investors in a market that lacks direction: be selective; be defensive; and be very attentive to valuation.

  • drug_stocks.jpg

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • merck_logo.jpg

    If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...

  • genentech_logo_1.jpg

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • rodman_renshaw_card.jpg

    Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • Forest Laboratories said Tuesday quarterly earnings fell 7 percent, hurt by a charge related to a product-licensing deal, and posted revenue that missed Wall Street expectations.

  • "The Noonday Demon" & "A Stone Boat" by Andrew Solomon

    In the "Sunday Styles" section of "The New York Times" the paper runs a very prestigious weekly feature known as "Vows". It's a relatively long write-up of someone's wedding and accompanied by pictures from the event. Yesterday, the Times highlighted the ceremony of Andrew Solomon and John Habich (for at least a few years now, The Times has included same-sex partnerships in its "Weddings/Celebrations").

  • Mergers and acquisitions are headed for another record year, fueled by a seemingly endless cascade of private-equity money.  “I can’t think of anything that’s off limits,” says Michael Kelly, managing director at Hamilton Lane. "There are good companies in any industry."

  • Financials and techs, two groups that pulled in the money last week, will be out in front of the news this week when earnings season is in full swing. Markets will also be watching key economic data, a parade of Fed speakers and whatever side show goes on when oil markets reopen, after last week's near six percent slide in crude.